Historical Valuation
Entrada Therapeutics Inc (TRDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 22.83 is considered Undervalued compared with the five-year average of -15.69. The fair price of Entrada Therapeutics Inc (TRDA) is between 1994.38 to 1998.79 according to relative valuation methord. Compared to the current price of 10.02 USD , Entrada Therapeutics Inc is Undervalued By 99.5%.
Relative Value
Fair Zone
1994.38-1998.79
Current Price：10.02
99.5%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Entrada Therapeutics Inc (TRDA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately -29.48% higher. Relative to its 5-year average P/B ratio of 1.41, the current P/B ratio is about -25.19% higher. Entrada Therapeutics Inc (TRDA) has a Forward Free Cash Flow (FCF) yield of approximately -36.01%. Compared to its 3-year average FCF yield of -6.63%, the current FCF yield is approximately 443.55% lower. Relative to its 5-year average FCF yield of -10.17% , the current FCF yield is about 253.96% lower.
P/B
Median3y
1.50
Median5y
1.41
FCF Yield
Median3y
-6.63
Median5y
-10.17
Competitors Valuation Multiple
AI Analysis for TRDA
The average P/S ratio for TRDA competitors is 19754.65, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA.O) exhibits a P/S ratio of 22.83, which is -99.88% above the industry average. Given its robust revenue growth of -91.75%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TRDA
1Y
3Y
5Y
Market capitalization of TRDA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TRDA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TRDA currently overvalued or undervalued?
Entrada Therapeutics Inc (TRDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 22.83 is considered Undervalued compared with the five-year average of -15.69. The fair price of Entrada Therapeutics Inc (TRDA) is between 1994.38 to 1998.79 according to relative valuation methord. Compared to the current price of 10.02 USD , Entrada Therapeutics Inc is Undervalued By 99.50% .
What is Entrada Therapeutics Inc (TRDA) fair value?
TRDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Entrada Therapeutics Inc (TRDA) is between 1994.38 to 1998.79 according to relative valuation methord.
How does TRDA's valuation metrics compare to the industry average?
The average P/S ratio for TRDA's competitors is 19754.65, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA) exhibits a P/S ratio of 22.83, which is -99.88% above the industry average. Given its robust revenue growth of -91.75%, this premium appears unsustainable.
What is the current P/B ratio for Entrada Therapeutics Inc (TRDA) as of Jan 10 2026?
As of Jan 10 2026, Entrada Therapeutics Inc (TRDA) has a P/B ratio of 1.06. This indicates that the market values TRDA at 1.06 times its book value.
What is the current FCF Yield for Entrada Therapeutics Inc (TRDA) as of Jan 10 2026?
As of Jan 10 2026, Entrada Therapeutics Inc (TRDA) has a FCF Yield of -36.01%. This means that for every dollar of Entrada Therapeutics Inc’s market capitalization, the company generates -36.01 cents in free cash flow.
What is the current Forward P/E ratio for Entrada Therapeutics Inc (TRDA) as of Jan 10 2026?
As of Jan 10 2026, Entrada Therapeutics Inc (TRDA) has a Forward P/E ratio of -2.48. This means the market is willing to pay $-2.48 for every dollar of Entrada Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Entrada Therapeutics Inc (TRDA) as of Jan 10 2026?
As of Jan 10 2026, Entrada Therapeutics Inc (TRDA) has a Forward P/S ratio of 22.83. This means the market is valuing TRDA at $22.83 for every dollar of expected revenue over the next 12 months.